Drugs and patents in ATC class L01XY - Combinations of antineoplastic agents

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
VYXEOS	cytarabine; daunorubicin
>Tradename	>Generic Name

Last updated: June 1, 2026

ATC Class L01XY patent landscape and market dynamics for combinations of antineoplastic agents: which drugs drive revenue, exclusivity, and generic/biosimilar risk

ATC L01XY covers combination antineoplastic regimens, not a single molecule. Patent and market dynamics are therefore regimen-specific and typically dominated by (i) the lead drug patent estate (small molecule or biologic), (ii) formulation and manufacturing-process patents for fixed-dose or co-pack products, and (iii) method-of-use and line-of-therapy patents tied to specific clinical endpoints and combinations.

Practical risk for generics and biosimilars generally concentrates in: (1) fixed-dose combinations with protectable dosing schedules and stability/performance claims, (2) combination regimens with data-anchored method-of-use claims, and (3) brands with paragraph IV filings on Orange Book-listed reference-listed drug (RLD) components.

What follows is a structured market-and-IP map of how L01XY combination products typically behave across major oncology combination categories, what patent “layers” control exclusivity, where challenges tend to cluster, and how to model launch risk.

Which ATC L01XY combination drugs have the strongest patent estates and why does combination IP usually last longer?

Patent layering in L01XY: what actually blocks competition

L01XY combination products usually sit on one or more of these IP layers:

Composition-of-matter (CoM) patents on individual antineoplastic agents
- Often the primary driver of legal exclusivity.
- Expiration is anchored to the lead compound filing date, PTA adjustments, and patent-term strategy.
Formulation and delivery system patents
- Fixed-dose combination tablets/capsules often have formulation patents on:
  - specific ratios and content uniformity ranges
  - dissolution profiles and particle-size distributions
  - stability under humidity/light
  - cryoprotectant or buffer choices for injectable combinations
- Co-pack strategies can still face patents on combination-specific containers, labeling, and stability.
Method-of-use patents for the regimen
- Claims often tie the combination to:
  - specific indications
  - specific lines of therapy
  - patient subgroups (biomarker-defined)
  - dosing frequency and sequence (induction vs maintenance)
- These can delay practical entry even when the base active ingredient is older.
Manufacturing and process patents
- Include:
  - scale-up steps
  - solvent systems
  - temperature/pressure controls
  - sterilization parameters for injectables
- Process patents can be a “backstop” even if CoM expires.

Why exclusivity can extend well beyond the “last API patent”

Combination regimens increase the number of claim opportunities. A competitive product that avoids CoM claims can still be blocked by:

a formulation equivalence argument (bioavailability, stability)
a manufacturing parameter claim
a regimen schedule claim tied to label indications

How many patents cover common L01XY combination regimens, and what counts as an “enforcement-relevant” patent?

Counting patents is not the same as counting enforcement risk

In L01XY, you can see dozens of patents listed across:

multiple patents on different RLDs (if the combination is co-packaged)
multiple method-of-use patents per indication and sponsor
formulation patents that do not map cleanly to generic design-arounds

Enforcement-relevant patents in L01XY typically are:

Orange Book-listed patents for an RLD (for FDA small molecule exclusivity and ANDA paragraph IV exposure)
Biologics-related exclusivity and sponsor-specific patent estates for combination biologics
High-likelihood method-of-use patents that map to label or drug compendia guidance

Which patent types show up most in litigation

Across oncology combinations, litigation most often centers on:

method-of-use patents that mirror trial endpoints and label wording
formulation patents tied to fixed-dose stability and dissolution
process patents tied to batch consistency for combination manufacturing

When does ATC L01XY combination exclusivity expire, and what milestones determine generic entry timing?

Key timing anchors for competition modeling

Competition timing for L01XY combinations usually depends on a mix of:

Regulatory exclusivity
- New chemical entity (NCE) exclusivity where applicable
- New clinical investigation exclusivity where applicable
- Orphan drug exclusivity for eligible oncology sub-populations
Patent expiration
- earliest expiration among listed blocking patents
- later expiration among formulation or method patents if no settlement or carve-out exists
Regulatory approval pathway
- ANDA for small molecules
- 505(b)(2) for reformulations or label expansions
- BLA and biosimilar pathways for biologics

Typical decision tree for an ANDA or 505(b)(2) entry

Identify whether the combination is an RLD fixed-dose or a co-pack.
Determine which patents are listed for the RLD in the Orange Book.
If those patents block, a paragraph IV strategy is evaluated:
- statutory non-infringement
- invalidity
Litigation and settlement drive the “real” launch date more than patent expiration alone.

What patents protect L01XY fixed-dose combination products: composition, formulation, and method-of-use patterns

Fixed-dose combination patents: the most litigated claim clusters

Fixed-dose combinations often concentrate IP on three claim clusters:

1) Ratio and content uniformity claims

patents define acceptable ranges for API ratio and content uniformity
generic products must demonstrate equivalence while avoiding infringement on exact ratios or ranges

2) Dissolution and release profile claims

dissolution curves can be claimed by:
- specifying media pH and times
- specifying percent dissolved thresholds
- linking release behavior to stability and efficacy

3) Stability claims

moisture/thermal stress stability claims can be asserted to block “same API, different formulation” approaches

Method-of-use claims: why design-arounds fail

Regimen method claims are typically broader than formulation engineering:

even if dissolution is redesigned, a generic may still infringe if the label-indicated use matches the patented regimen schedule.

Which companies challenge ATC L01XY patents with paragraph IV filings, and how do settlements usually structure launch?

Company behavior that drives market outcomes

In oncology combinations, challenger behavior usually clusters around:

established generic houses filing paragraph IV to gain time while litigating
505(b)(2) entrants filing on reformulations or switching components
biosimilar sponsors targeting biologic components where combination regimens are not independently protectable

Settlement patterns

Settlement agreements in combination regimens often include:

agreed “carve-out” launches for non-overlapping indications or dosing schedules
delayed launch dates for fixed-dose combos while allowing single-agent entries
supply agreements for transitional periods

Practical impact: settlement frequently controls entry date more reliably than the final adjudication timeline.

What is the Orange Book status of L01XY combination products: how to interpret RLD and listed patents for launch risk

How Orange Book listings drive ANDA risk

For any L01XY combination product that is an RLD:

patents listed in the Orange Book can be:
- blocking patents tied to approval
- non-blocking listed patents not tied to approval
paragraph IV exposure attaches to Orange Book-listed patents.

How to map listings to a generic entry scenario

If a fixed-dose combination has multiple listed patents, generic launch hinges on the expiration or clearance of the last blocking patent.
Co-pack combinations can create a different mapping:
- each component can have its own Orange Book listing and expiration
- the co-pack regimen still may have method-of-use claims asserted outside Orange Book depending on jurisdiction and enforcement strategy

How do biosimilars impact L01XY combination regimens when the combination includes biologics?

Biosimilar entry risk is component-specific

If an L01XY regimen includes a biologic:

biosimilar entry risk is driven by the lead biologic’s:
- reference product exclusivity
- patent estate for CoM and biological function
- formulation and manufacturing process patents for the biologic

Combination-specific protection still matters

Even after biosimilar approval for the biologic component, combination-specific:

method-of-use
regimen schedule
device and co-administration handling can still constrain interchangeability in practice, particularly for fixed combination products.

What patent litigation affects L01XY combination products: common venue dynamics and typical outcomes

Litigation timeline that affects market revenue

Oncology combination disputes commonly follow:

filing of paragraph IV ANDA triggers automatic FDA stay (where applicable)
district court litigation (often fast but variable)
settlement converting to stipulated launch dates

The market consequence is that the “relevant launch date” for investors often tracks settlement windows rather than statutory expiration.

Typical outcomes that shape competitive entry

early settlements that cap entry
design-around approvals that still face injunction risk
partial settlements permitting launch for:
- specific patient subgroups
- specific lines of therapy

Which formulation patents are hardest to design around for L01XY combinations?

Formulation patents that are difficult to avoid

Generic entrants frequently face infringement risk on:

dissolution criteria and time-point thresholds
stability under specified conditions
container closure system claims that affect shelf-life and performance

Strategy that still succeeds

Design-around often requires:

using different excipient systems and proving comparable performance without crossing claimed thresholds
selecting alternative release mechanisms not captured by dissolution curve claims
avoiding claimed stability conditions tied to measured shelf-life outcomes

How does ATC L01XY compare with other oncology combination classes (L01XX, L01XE): what differs in patent risk?

Combination class comparison

L01XY is a combination grouping, so its patent risk concentrates on regimen-specific IP and fixed-dose/formulation layers.
Other classes may be more molecule-centric (single agent or distinct mechanistic grouping), making:
- earlier predictability based on a single CoM expiration
- fewer regimen-method claim clusters

Net effect: L01XY often shows higher “total patent density” per competitive attempt because multiple patents can map to the same clinical regimen.

Commercial exposure: how L01XY combination revenue is typically distributed by regimen and geography

Revenue concentration

In oncology combinations, revenue tends to concentrate in:

high-incidence solid tumors with label expansions
regimens with long maintenance phases
settings where the combination is standard of care (first-line or perioperative)

Geography

Patent enforcement and generic launch typically vary by:

local patent coverage breadth
settlement enforceability and local court speed
regulatory willingness to approve alternatives with partial label differences

Key Takeaways

L01XY combinations have regimen-specific IP estates with layered protection: CoM on lead agents, fixed-dose formulation patents, method-of-use claims, and process patents.
Exclusivity and launch timing are driven by the last blocking Orange Book patent on the RLD and, in practice, by settlement windows after paragraph IV challenges.
Generic and biosimilar risk is component-specific for the biologic or small-molecule APIs, but combination-specific protection (formulation and method-of-use) often constrains practical entry even after component approval.
Litigation and settlements typically dictate launch dates more reliably than statutory patent expiration timelines.

FAQs

1) What drives the biggest delays for L01XY generic launches: patent expiration or regulatory exclusivity?
Blocking Orange Book patents and settlement-triggered FDA stays usually dominate realized launch timing.

2) Can a generic launch a single agent component while the L01XY fixed-dose combination remains blocked?
Often yes, depending on Orange Book scope and method-of-use enforcement, but co-administration claims can still restrict market uptake.

3) How do method-of-use patents affect a “non-overlapping” generic label strategy for L01XY?
If the patented claims align with core label language or compendia-supported regimen use, label carve-outs can reduce but not eliminate infringement risk.

4) Do biosimilars approved for one indication automatically reduce L01XY combination exclusivity risk?
No. Biosimilar approval for a biologic component does not automatically clear combination method-of-use and regimen scheduling protections.

5) Why are fixed-dose formulation patents more defensible in L01XY than in many single-agent categories?
Because they tie technical equivalence to performance and stability in the combined product, increasing the likelihood that design-arounds hit claimed dissolution or stability thresholds.

References (APA)

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-01).
FDA. Regulatory Exclusivity for Human Drugs. U.S. Food and Drug Administration. https://www.fda.gov/drugs/fees-and-forms/fda-user-fee-exclusivity (accessed 2026-06-01).
FDA. Biosimilars. U.S. Food and Drug Administration. https://www.fda.gov/drugs/biologics-biosimilars/biosimilars (accessed 2026-06-01).